Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
Contineum Therapeutics, Inc. (CTNM) reported that its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not meet its primary efficacy endpoint. The study evaluated improvement from baseline in Montgomery-Åsberg Depression Rating Scale total score at Day 5 versus placebo. JNJ-5120/PIPE-307 was reported to be well tolerated with no new safety signals. Johnson & Johnson, which is developing the drug under a global license and development agreement with Contineum, is continuing to analyze the Phase 2 data, including prespecified exploratory endpoints, to assess the clinical relevance of the findings and determine potential next steps.
Contineum Therapeutics, Inc. (CTNM) reported that CEO and President Carmine N. Stengone exercised options to acquire 2,500 shares of Class A common stock on September 8, 2026 at an exercise price of $1.01 per share and sold 2,500 shares on the same day at a weighted average price of $16.4566 per share. The option was granted under Contineum Therapeutics’ 2012 Equity Incentive Plan, is fully vested, and after this exercise 274,430 option shares from this award remain outstanding. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
Contineum Therapeutics, Inc. (CTNM) reports that securities associated with Carmine Stengone are being notified for potential sale under Rule 144. The notice covers a planned sale of 2,500 shares of common stock on September 8, 2026, following recent 10b5-1 sales over the prior three months.
Contineum Therapeutics, Inc. (CTNM) is the issuer for a planned resale of common stock by officer Daniel Lorrain under Rule 144. The notice covers 9,520 common shares, with an aggregate market value of $154,604.80, expected to be sold through Morgan Stanley Smith Barney LLC on or about September 1, 2026. The shares consist of 5,350 shares underlying stock options and 4,170 shares from restricted stock units originally granted on May 9, 2017. The filing also lists multiple prior Rule 10b5-1 plan sales of CTNM common stock over the preceding three months.
Contineum Therapeutics, Inc. has a large shareholder group led by Balyasny Asset Management entities and Dmitry Balyasny reporting beneficial ownership of Class A common stock. Through Atlas Diversified Master Fund, Ltd., they are deemed to beneficially own 2,335,550 shares of Class A common stock, with sole voting and sole dispositive power over these shares and no shared power. This position represents approximately 7.14% of the Class A common stock, based on 32,723,877 shares outstanding as of April 30, 2026. Atlas Diversified Master Fund, Ltd. has the right to receive dividends and sale proceeds on the reported securities.
Contineum Therapeutics, Inc. CEO and President Carmine N. Stengone exercised stock options for 2,500 shares of Class A common stock at an exercise price of $1.01 per share and sold 2,500 shares at a weighted average price of $16.0116 per share, with trades between $16.00 and $16.06. The options were granted under the company’s 2012 Equity Incentive Plan and are fully vested, leaving 276,930 options outstanding after the exercise. All reported transactions on August 3, 2026 were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
CTNM reports that an affiliate, Morgan Stanley Smith Barney LLC Executive Financial Services, intends to sell 2,500 shares of common stock on NASDAQ on August 3, 2026, in connection with an exercise of stock options for cash. The filing also lists prior sales under a Rule 10b5-1 trading plan for Carmine Stengone, including 2,500 common shares sold on July 8, 2026 for $40,000.00 and 10,000 common shares sold on June 30, 2026 for $160,080.00.
CTNM insider Daniel Lorrain has filed to sell common stock under Form 144. The planned sale involves 9,520 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 3, 2026 on NASDAQ.
The shares relate to equity awards including 4,170 restricted stock units granted on May 9, 2017 and an exercise of stock options for 5,350 shares dated August 3, 2026, with cash as the payment method for the option exercise. The filing also lists recent Rule 10b5-1 plan sales of CTNM common stock by Lorrain over the prior three months in multiple tranches.
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory and fibrotic diseases. Lead asset PIPE-791, an LPAR1 inhibitor, is in PROPEL-IPF, a global Phase 2 trial in idiopathic pulmonary fibrosis, and has shown encouraging Phase 1b data in chronic pain. Partnered drug PIPE-307, an M1 receptor inhibitor licensed to J&J, is in a Phase 2 depression study (Moonlight-1) with 107 participants enrolled.
For the quarter ended June 30, 2026, the company reported no revenue, operating expenses of $17.4 million and a net loss of $15.2 million, or $0.40 per share$24.3 million and general and administrative expenses were $10.0 million, leading to a six‑month net loss of $29.6 million.
Liquidity remains strong, with $236.6 million in cash, cash equivalents and marketable securities as of June 30, 2026. Management states these resources are expected to fund operations for at least 12 months. An amended at‑the‑market program permits up to $100.0 million of additional Class A common stock sales, none of which were used in the first half of 2026.
Contineum Therapeutics reported second-quarter 2026 results and progress across its pipeline of oral small-molecule drugs for inflammatory and fibrotic diseases. The company is dosing patients in PROPEL-IPF, a 26-week global Phase 2 trial of PIPE-791 in approximately 324 idiopathic pulmonary fibrosis patients, with over 55 sites active in eight countries. Johnson & Johnson completed enrollment of 107 adults in the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder. PIPE-791 also produced positive topline safety and exploratory pain data in an exploratory Phase 1b chronic pain study.
Contineum streamlined discovery efforts and implemented a limited workforce reduction, including the departure of Chief Scientific Officer Daniel Lorrain, to focus resources on its highest-potential programs. Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026, and the company believes this supports operations through mid-2029. In the quarter, research and development expenses were $12.7 million (down 10% year over year), general and administrative expenses were $4.7 million (up 23%), and net loss was $15.2 million compared with $16.0 million a year earlier.